Synonym
GW806742X; GW-806742X; GW 806742X; NSC756366; NSC 756366; NSC-756366
IUPAC/Chemical Name
3-(4-(Methyl(4-(3-(4-(trifluoromethoxy)phenyl)ureido)phenyl)amino)pyrimidin-2-ylamino)benzenesulfonamide
InChi Key
SNRUTMWCDZHKKM-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H22F3N7O4S/c1-35(22-13-14-30-23(34-22)31-18-3-2-4-21(15-18)40(29,37)38)19-9-5-16(6-10-19)32-24(36)33-17-7-11-20(12-8-17)39-25(26,27)28/h2-15H,1H3,(H2,29,37,38)(H,30,31,34)(H2,32,33,36)
SMILES Code
O=S(C1=CC=CC(NC2=NC=CC(N(C)C3=CC=C(NC(NC4=CC=C(OC(F)(F)F)C=C4)=O)C=C3)=N2)=C1)(N)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X has activity against VEGFR2 (IC50=2 nM).
In vitro activity:
Firstly, it was proved that non-selective AURKA and AURKB inhibitors GW809897X and GW806742X treatment reduced cell proliferation of leukemia cell line (K-562) with a potency constant IC50 of > 5 µM and 1.47 µM, respectively.
Reference: Sci Rep. 2020 Dec 4;10(1):21272. https://pubmed.ncbi.nlm.nih.gov/33277547/
In vivo activity:
In addition, airway inflammation and lung eosinophil infiltration were reduced asthmatic mice in response to GW80 (GW806742X) treatment (Fig. 6H–K). In summary, the ability of the necroptotic inhibitor GW80 to attenuate pathology in an IL-33-dependent Asp.-induced asthma model suggests a role for necroptosis in IL-33 release in asthma.
Reference: FEBS J. 2019 Feb;286(3):507-522. https://pubmed.ncbi.nlm.nih.gov/30576068/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
100.0 |
174.35 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
573.55
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Moreira-Nunes CA, Mesquita FP, Portilho AJS, Mello Júnior FAR, Maués JHDS, Pantoja LDC, Wanderley AV, Khayat AS, Zuercher WJ, Montenegro RC, de Moraes-Filho MO, de Moraes MEA. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia. Sci Rep. 2020 Dec 4;10(1):21272. doi: 10.1038/s41598-020-78024-8. PMID: 33277547; PMCID: PMC7718893.
2. Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2019 Feb;286(3):507-522. doi: 10.1111/febs.14738. Epub 2019 Jan 4. PMID: 30576068.
In vitro protocol:
1. Moreira-Nunes CA, Mesquita FP, Portilho AJS, Mello Júnior FAR, Maués JHDS, Pantoja LDC, Wanderley AV, Khayat AS, Zuercher WJ, Montenegro RC, de Moraes-Filho MO, de Moraes MEA. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia. Sci Rep. 2020 Dec 4;10(1):21272. doi: 10.1038/s41598-020-78024-8. PMID: 33277547; PMCID: PMC7718893.
In vivo protocol:
1. Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2019 Feb;286(3):507-522. doi: 10.1111/febs.14738. Epub 2019 Jan 4. PMID: 30576068.
1: Moreira-Nunes CA, Mesquita FP, Portilho AJS, Mello Júnior FAR, Maués JHDS, Pantoja LDC, Wanderley AV, Khayat AS, Zuercher WJ, Montenegro RC, de Moraes- Filho MO, de Moraes MEA. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia. Sci Rep. 2020 Dec 4;10(1):21272. doi: 10.1038/s41598-020-78024-8. PMID: 33277547; PMCID: PMC7718893.
2: Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2019 Feb;286(3):507-522. doi: 10.1111/febs.14738. Epub 2019 Jan 4. PMID: 30576068.
3: Lusthaus M, Mazkereth N, Donin N, Fishelson Z. Receptor-Interacting Protein Kinases 1 and 3, and Mixed Lineage Kinase Domain-Like Protein Are Activated by Sublytic Complement and Participate in Complement-Dependent Cytotoxicity. Front Immunol. 2018 Feb 23;9:306. doi: 10.3389/fimmu.2018.00306. PMID: 29527209; PMCID: PMC5829068.
4: González-Juarbe N, Gilley RP, Hinojosa CA, Bradley KM, Kamei A, Gao G, Dube PH, Bergman MA, Orihuela CJ. Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. PLoS Pathog. 2015 Dec 11;11(12):e1005337. doi: 10.1371/journal.ppat.1005337. PMID: 26659062; PMCID: PMC4676650.
